Mounjaro's Drug Price Increase and What It Means for Your Treatment Cost

What Eli Lilly's list-price change actually changed

The September 2025 list-price rise was steep, and it was widely reported. Eli Lilly's UK list price for the highest-dose Mounjaro pen moved from roughly £122 to roughly £330, a jump that fed directly through to private-clinic pricing across the board. Lower doses were also repriced, though the percentage increases varied. If you were quoted a price before that date, the figure you were given is now out of date.

Private providers price above the list price to cover their operating costs, so the retail cost of any given dose is higher than the list price itself. That gap varies by provider. The price you see advertised for a specific dose may or may not include the consultation, the prescription charge, delivery and any follow-up clinical review, which brings us to the decision the increase actually forces.

The practical thing to do in under a minute: pull up the current Mounjaro pricing breakdown on our treatment page and compare it against quotes you've received elsewhere, checking what each figure actually covers. A lower headline number that excludes a prescription charge and delivery can end up costing more by the time you've totted it all up.

What headline prices often leave out, and why it matters more now

Before September 2025, price differences between providers were real but relatively contained. Now, with list prices higher, the gap between what a headline number says and what you actually pay has more room to grow. A quoted figure might cover the pen only. It might exclude a consultation fee charged separately. Delivery (especially tracked, temperature-controlled delivery for a refrigerated medicine) is often an add-on. Clinical review before a dose change is sometimes billed as a separate appointment.

None of that is hidden in the sense of being dishonest, but it does mean the number in the advert is rarely the number on the receipt. The full cost picture for Mounjaro in the UK covers the components worth comparing line by line.

For people who started treatment before the increase, there's a related question: does the price rise affect every dose, or is the impact concentrated at the top of the titration schedule? The short answer is that the 5mg price increase and the changes at the entry doses were meaningful but smaller in absolute terms than at the higher strengths. The dose your prescriber lands you on for maintenance matters for your ongoing monthly outlay.

Where nume sits, and why we entered this differently

We're not the cheapest option. That's a deliberate choice, not a gap we're working to close. The September Mounjaro price increase, which affected list pricing across all doses, didn't change that position; it sharpened it. What we offer is one transparent figure that covers the clinical consultation, the prescription, the medicine itself, and free next-working-day DPD delivery. There's no aftercare surcharge, no renewal fee, no separate prescription charge bolted on at checkout.

Our prescribers (you can read about our clinical oversight on the clinical team page) review every consultation the same day, personally. Every repeat order goes through clinical re-review before dispatch. That's not something a lower price point generally includes.

If you want to see what's covered and check whether you meet the clinical criteria, the treatment page is the right place to start. Eligibility is assessed individually; BMI alone doesn't determine the outcome.

Why 'cheapest' is the wrong question for a prescription medicine

Mounjaro is a prescription-only medicine that requires cold-chain storage, a licensed supply chain, and clinical oversight before and during treatment. After the MHRA warned in October 2023 about counterfeit weight-loss pens (and following large seizures of fake tirzepatide pens through 2025, including the first UK illicit manufacturing site producing counterfeit pens) the regulator has been clear: prices that look unusually low for a genuine licensed product are a red flag, not a bargain. You can verify any online pharmacy on the GPhC register in seconds.

The MHRA's public guidance on GLP-1 medicines sets this out plainly: these are regulated prescription medicines, not consumer goods where lowest price signals best value. A small saving on a counterfeit or clinically unsupervised supply isn't a saving at all, which is worth bearing in mind if you've come across a provider advertising Mounjaro in the UK with no price increase since the September 2025 list-price change. The weight-loss treatment overview explains what legitimate private access looks like from a safety standpoint.

Price is worth knowing. It's just not the measure that tells you whether a supply is safe, supervised, and genuine. That's the question worth answering first.